Singapore markets closed

Cellectis S.A. (CLLS)

NasdaqGM - NasdaqGM Delayed price. Currency in USD
Add to watchlist
2.0900+0.0600 (+2.96%)
At close: 04:00PM EDT
2.1600 +0.08 (+3.85%)
Pre-market: 05:46AM EDT
Full screen
Trade prices are not sourced from all markets
Previous close2.0300
Open2.0600
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.0356 - 2.0900
52-week range0.9630 - 3.7740
Volume9,865
Avg. volume56,365
Market cap209.196M
Beta (5Y monthly)3.20
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Monthly information on share capital and company voting rights

    (Article 223-16 of General Regulation of the French financial markets authority) PARIS, July 05, 2024 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights06/30/2024100,093,63588,029,364 For further information on Cellectis, please contact: Media contact: Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77

  • GlobeNewswire

    Cellectis Reports Results from Shareholders Meeting Held on June 28, 2024

    NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which approximately 40% of shares were exercised, resolutions 1 through 28 were adopted and resolution 29 was rejected, co

  • GlobeNewswire

    Cellectis Publishes a Scientific Article Unveiling Three Key Factors for Efficient TALE Base Editing

    NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a manuscript in Scientific Reports, demonstrating how three key factors can be determinant for efficient TALE base editing. TALE base editors are a recent and important addition to the gene editing landscape. By design, TALE